Testing benralizumab in adults with severe eosinophilic asthma

Trial details

Who runs it

Nantes University Hospital

Trial code

NCT04565483EU 2024-514843-27-00

Record updated

26 April 2024

Original description

The objective of the study is to establish the predictive value of early blood gene expression signature of Benralizumab response associated with a significant reduction of the number of exacerbations in treated severe asthmatic patients.Read full original descriptionShow less

Predictive Signature of Benralizumab Response

The objective of the study is to establish the predictive value of early blood gene expression signature of Benralizumab response associated with a significant reduction of the number of exacerbations in treated severe asthmatic patients.

This trial is a French, multicenter and no-randomized trial. Patients enrolled will be clinically followed for 16 months (the treatment period: 12 months and 1 month follow-up; 6 clinical visit on site and in phone call at 13 months)

Inclusion: Patients between 18 and 75 years old; Patients diagnosed with severe asthma (Chung and al, Eur Respir J 2014), i.e.:; asthma requiring high doses of ICS (>1000 microgram per day of Beclomethasone or equivalent) associated with LABA and/or systemic corticosteroids to be controlled over one year,; and/or uncontrolled asthma despite the later medications,; and/or a controlled asthma worsening after decreasing medications,; Documented historical reversibility of FEV1 ≥12% and FEV1 gain ≥ 200 milliliter; ACQ-7 score ≥ 1,5 at M0; ≥ 3 exacerbations in the 12 months prior to screening visit M-1; Eosinophil blood count ≥ 0,3 G/L at inclusion visit or in the 12 months prior to the inclusion visit. If eosinophil blood count is ≥ 0,15 G/L and < 0,3 G/L, an eosinophilic phenotype defined by at least 1 of the following criteria will be required:; Fractional Exhaled Nitric Oxide (FeNO) > 25 ppm at inclusion visit or in the 12 months prior to the inclusion visit; Sputum eosinophils ≥ 3% at inclusion visit or in the 12 months prior to the inclusion visit; Patients who provide written informed consent prior to participation in the study.

Exclusion: Patients requiring other immunosuppressive and immunomodulator drugs; Patients diagnosed with difficult-to-treat asthma and/or with uncontrolled asthma differential diagnosis according to the judgment of the investigator (e.g., vocal cord dysfunction, gastroesophageal reflux disease, granulomatous eosinophilic vasculitis, obstructive sleep apnea syndrome, hyperventilation syndrome, allergic broncho-pulmonary aspergillosis, Carrington disease, DIPNECH, asthma/COPD overlap syndrome); Active malignancy or malignancy in remission over less than 5 years; Active parasitic infection or parasitic infection in the past 24 weeks; Hypersensitivity to Benralizumab or to any of the excipients of Fasenra® (histidine, histidine hydrochloride monohydrate, trehalose dihydrate, polysorbate 20); SARS-COV2 infection; Patients under psychiatric condition altering their comprehension and their ability to give informed consent; Non-adherent patients to inhaled treatment (ICS + LABA); Active smokers or former smokers exceeding 20 packs year; Exacerbation at inclusion visit M0; Patients requiring other biotherapy than Benralizumab, with or without French's marketing authorisation in severe asthma; Patients requiring other biotherapy than Benralizumab that affects the immune system; Pregnancy, lactation, or patients with childbearing potential refusing efficient contraceptive method; Patients already enrolled in a clinical interventional research; Patients not affiliated to a health insurance plan; Patients under guardianship, curators or safeguard of justice.

ClinicalTrials.gov NCT04565483 · EU CTIS 2024-514843-27-00